Steve Springer, MD
Family Medicine · Lake Charles, LANPI 1477538619
Payments from drug & device makers
Across 331 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$972
- AbbVie$744
- Lilly USA, LLC$609
- Novo Nordisk$451
- GSK$436
- Boehringer Ingelheim$393
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,248100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $972 |
| AbbVie(2 entities) | 34 | $744 |
| Lilly USA, LLC | 35 | $609 |
| Novo Nordisk | 30 | $451 |
| GSK | 20 | $436 |
| Boehringer Ingelheim | 24 | $393 |
| Dexcom, Inc. | 9 | $259 |
| Novartis | 15 | $245 |
| Abbott | 15 | $243 |
| Pfizer | 16 | $206 |
| Phathom Pharmaceuticals, Inc. | 11 | $178 |
| Exact Sciences | 8 | $174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $133 |
| Bayer | 6 | $130 |
| Sanofi-aventis U.S. LLC | 9 | $126 |
| Esperion Therapeutics, Inc. | 8 | $124 |
| Merck | 7 | $113 |
| Globus Medical | 1 | $107 |
| Daiichi Sankyo Inc. | 4 | $77 |
| Smith+Nephew | 2 | $69 |
| Musculoskeletal Transplant Foundation Inc. | 3 | $64 |
| Astellas Pharma US Inc | 3 | $59 |
| Amgen | 3 | $53 |
| Noven Therapeutics, LLC | 2 | $47 |
| Amarin Pharma, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Currax Pharmaceuticals LLC | 1 | $21 |
| Organogenesis Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Shionogi Inc | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
- DEXCOM CGM$124
- FARXIGA$119
- BREZTRI$119
- Sable$107
How this compares
$6,254 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 270 | $315,056 |
| FarxigaDapagliflozin Propanediol | 199 | $165,693 |
| OzempicSemaglutide | 104 | $147,909 |
| JardianceEmpagliflozin | 145 | $135,022 |
| EliquisApixaban | 104 | $80,579 |
| TrulicityDulaglutide | 55 | $67,640 |
| JanuviaSitagliptin Phosphate | 76 | $59,275 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $28,797 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 112 | $15,845 |
| LinzessLinaclotide | 19 | $15,464 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $13,688 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $8,907 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $8,106 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 635 | $7,702 |
| Atorvastatin Calcium | 771 | $5,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $609 | $382,696325 claims |
| AstraZenecaFarxiga | $972 | $165,693199 claims |
| Novo NordiskOzempic | $451 | $147,909104 claims |
| Boehringer IngelheimJardiance | $393 | $135,022145 claims |
| PfizerEliquis, Premarin | $206 | $84,774115 claims |
| MerckJanuvia | $113 | $59,27576 claims |
| GSKTrelegy Ellipta | $436 | $28,79737 claims |
| AbbVieLinzess, Synthroid | $744 | $17,51752 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $133 | $4,59512 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $2,679331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Lake Charles
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Joshua WhatleyLake Charles$366K
- Robert VangossenLake Charles$14K
- Clinton GuilloryMonroe$18.5M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.